Drug Type Small molecule drug |
Synonyms 克利加巴林, HSK 16149, HSK-16149 + [2] |
Target |
Mechanism CACNA2D1 blockers(Voltage-gated calcium channel alpha2/delta subunit 1 blockers) |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date CN (15 May 2024), |
Regulation- |
Molecular FormulaC12H19NO2 |
InChIKeyWCEFMBSFXJUREW-LIJGXYGRSA-N |
CAS Registry2209104-84-5 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetic peripheral neuropathic pain | CN | 15 May 2024 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neuralgia, Postherpetic | NDA/BLA | CN | 13 Sep 2023 | |
Neuralgia | Phase 3 | - | 30 May 2024 | |
Peripheral neuralgia | Phase 3 | CN | 17 Feb 2022 | |
Pain, Postoperative | Phase 2 | CN | 08 Mar 2023 | |
Post-herpetic neuritis | Phase 1 | CN | 20 Mar 2023 | |
Renal Insufficiency | Phase 1 | CN | 12 Dec 2022 | |
Diabetic peripheral neuropathy | Phase 1 | CN | 01 Apr 2021 | |
Fibromyalgia | IND Approval | CN | 17 Apr 2024 |
NCT06122012 (ADA2024) Manual | Phase 2 | 134 | Crisugabalin with Acetyl-Levo-Carnitine | kfklrqycbn(ztaptottca) = anljcumtfu bmxohtwgfh (lochhifynr ) | Positive | 21 Jun 2024 | |
lipoic acid (LA) combined with acetyl-levo-carnitine | kfklrqycbn(ztaptottca) = rrrnufsgml bmxohtwgfh (lochhifynr ) | ||||||
Not Applicable | - | Placebo | perorgpjqe(wtngvdblvw) = dqudbhleir ulzsmmrstn (alnkwccbni ) | Positive | 20 Jun 2023 | ||
perorgpjqe(wtngvdblvw) = wpmirsclpi ulzsmmrstn (alnkwccbni ) |